My perspective: Time doesn't control pricing and value, opportunity and events (developments) do. Assessing the potential upside of ARTH is difficult due to a lack of information. This situation is typical of life science products as the events for companies in this sector don't occur in rapid fire sequence as they might in other sectors. Also, ARTH has cried 'eureka' a few times. I watch for events, not the calendar.
Question: There is a company - 3-D Matrix Medical Technology in Waltham, MA. It is the US sub of a Japanese company. 3-D has a 'self assembling' peptide based on MIT technology that it is using as the basis for at least one medical device. The parent company has been around for a long time. It is pubic on a Japanese exchange. 3-D Matrix USA has submitted a 510(k) application to FDA in late 2018, for an ENT application. ENT is not considered an internal surgical application from FDA perspective. Does anyone know much about 3-D or how its technology stacks up againt AC5? People on this board must know about 3-D. Comments?
Market Data 
Markets 
AI
